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ABSTRACT
Introduction Up to 10% of adolescents report self- harm 
in the previous year. Non- fatal repetition is common 
(18% in 1 year), death from any cause shows a fourfold 
and suicide a 10- fold excess. Despite the scale of the 
problem, there is insufficient evidence for effective 
interventions for self- harm. Those who self- harm do so 
for a variety of different reasons. Different treatments may 
be more effective for subgroups of adolescents; however, 
little is known about which subgroups are appropriate for 
further study. This protocol outlines a systematic review 
and individual participant data meta- analysis (IPD- MA) to 
identify subgroups of adolescents for which therapeutic 
interventions for self- harm show some evidence of 
benefit.
Methods and analysis A systematic literature search 
was conducted in August 2019 (including Cochrane 
Library, Embase, trial registers and other databases). An 
update search is planned. Study selection will identify 
randomised controlled trials examining interventions to 
reduce self- harm in adolescents who have self- harmed 
and presented to services. Identified research teams will 
be invited to contribute data and form a collaborative 
group. Two- stage IPD- MA will be used to evaluate 
effectiveness of different therapeutic interventions 
compared with any active or non- active control on 
repetition of self- harm, general psychopathology, 
depression, suicidal ideation, quality of life and death. 
Subgroup analyses will identify adolescent subgroups 
in whom different therapeutic interventions may be 
more effective. Meta- regression will explore moderating 
study and intervention effects. Sensitivity analyses will 
incorporate aggregate data from studies lacking IPD and 
test the robustness of results to methods for handling 
missing data, within- study clustering, non- adherence and 
study quality.
Ethics and dissemination Ethical approval is provided 
by the University of Leeds, Faculty of Medicine and Health 
Ethics Committee (18-098). Outcomes will inform research 
recommendations and will be disseminated internationally 
through the collaborative group, a service user advisory 
group, open- access peer- reviewed publication and 
conference presentations.
PROSPERO registration number CRD42019152119.
INTRODUCTION
Self- harm is common in adolescents and a 
major issue of public health concern in the 
UK and globally.1 One in twenty 11–16 year- 
olds, and one in seven 17–19 year- olds, report 
having self- harmed or attempted suicide at 
some point; with rates in girls twice that of 
boys.2
Self- harm in adolescents has serious conse-
quences; rates of death from any cause show a 
fourfold and suicide a 10- fold excess risk,3 and 
suicide is the second most common cause of 
Strengths and limitations of this study
 ► Much research in this field spans the adolescent and 
adult divide (ie, participants aged 14–25); individual 
participant data meta- analysis (IPD- MA) allows us to 
increase the pool of studies and participants through 
the inclusion of subsets of participants from partially 
eligible studies.
 ► IPD- MA will provide an increased sample size to 
permit meaningful subgroup analyses unavailable to 
individual studies; a more reliable estimate of the 
effect of therapeutic interventions for self- harm; and 
flexibility in analysis to handle sources of between- 
study and within- study heterogeneity.
 ► Obtaining agreements with primary authors of eli-
gible studies to share data, development of formal 
data sharing agreements and the successful transi-
tion of data is the most likely obstacle to successful 
completion.
 ► Non- standardised baseline data may limit the avail-
able subgroup analyses and variation in the defini-
tion and follow- up periods for our primary outcome, 
repeat self- harm, requires careful derivation in the 
IPD- MA.
 ► Within IPD- MA, there is limited methodological guid-
ance to account for treatment- related clustering; 
within- study clustering using standardised mean 
differences; and study, provider and patient- level 
mediators.
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death in 10–24 year- olds.4 Non- fatal repetition is common 
with 1- year rates of hospital reattendance at 18%.5
Any intervention that reduced self- harm would, as 
well as saving lives, result in significant reductions in 
family and peer distress. Effective interventions would 
also reduce significantly the cost to the health service in 
providing support for repeated self- harm.
A recent updated systematic review (25 studies, 
n=2962) found a small overall effect on repetition, with 
suggestive effect sizes for dialectical behaviour therapy, 
family- centred therapy, mentalisation- based therapy 
and interpersonal therapy.6 7 However, a single effec-
tive intervention to prevent repeat self- harm has not 
yet been identified.6–8 Published studies to date have 
often been small with mixed and varied heterogeneous 
samples.
Most published studies have been pragmatic and have 
recruited participants presenting to services without 
major restrictions on eligibility, in order to enhance 
generalisability. Those who self- harm do so for a variety 
of different reasons. It is therefore possible that there are 
subgroups of adolescents who respond better to all or 
some interventions.
We know that factors such as age, gender, lesbian, 
gay, bisexual, or transgender (LGBT) status, number of 
previous self- harm attempts, method of self- harm, psychi-
atric history and status (in particular depression9) carry 
increased risk for repetition. A recent National Confiden-
tial Inquiry into Suicide and Homicide indicated that of 
285 suicide deaths that occurred in youths aged 10–20, 
52% had a history of self- harm, while 58% expressed 
thoughts of suicide or hopelessness.10 This raises the 
possibility that either treatment and/or adolescent and 
family variables may predict better (or worse) outcomes 
and be important mechanisms underpinning effective 
interventions.
An individual participant data meta- analysis (IPD- MA) 
would provide more reliable estimates of the effects of 
therapeutic interventions for self- harm than conven-
tional meta- analyses that rely on aggregated information 
and reported analyses,11 and would permit meaningful 
subgroup analyses previously unavailable to individual 
studies due to the increased sample size.
The Reducing Self- harm in Adolescents: Individual Partic-
ipant Data meta- analysis (RISA- IPD) project aims to build 
on previous systematic reviews6–8 12–14 and conduct an 
IPD- MA of randomised controlled trials (RCT) of any 
control versus therapeutic intervention to reduce subse-
quent self- harm in adolescents who have already self- 
harmed and presented to services. The project objectives 
are to:
1. Conduct a systematic literature search and systematic 
study selection to identify relevant research teams and 
studies.
2. Invite identified research teams to contribute data to 
enable us to form a collaborative group and conduct 
IPD- MA.
3. Conduct IPD- MA to:
1. Provide updated estimates of the pooled treatment 
effect of therapeutic interventions for self- harm 
compared with any non- active control.
2. Identify subgroups of adolescents based on 
participant- level covariates, in whom therapeutic in-
terventions are more effective.
3. Explore moderating study and intervention effects.
4. Provide clearly defined research recommendations for 
future clinical practice and RCTs.
METHODS
Study design
Systematic review and IPD- MA of RCTs of therapeutic 
interventions to reduce subsequent self- harm in adoles-
cents who have already self- harmed and presented 




All adolescents of any gender or ethnicity:
 ► Aged 11–18, where 18 is defined as up to the 19th 
birthday at the point of randomisation.
 ► Who have self- harmed at least once prior to rando-
misation and consequently presented to clinical 
services, where self- harm includes suicide attempt and 
excludes suicidal ideation without explicit self- harm.
No restrictions are placed on whether participants have 
comorbid mental or physical health conditions or intel-
lectual disability.
Interventions
Any type of intervention, delivered by any type of care 
provider(s), one of the aims of which is to reduce subse-
quent self- harm. This includes psychological or pharma-
cological interventions, with/without individual, group 
or family involvement; delivery of social/service support; 
and interventions of any intensity including self- help. 
Prevention- based interventions not targeted specifically 
at adolescents who have presented to clinical services with 
self- harm and intensive inpatient- based interventions are 
excluded.
Evidence synthesis will be conducted by therapeutic 
intervention grouped by consensus of RISA- IPD clinical 
coapplicants (DC, DO, PF), according to the study inter-
vention’s published descriptions, theoretical underpin-
nings, available supplementary material and manuals and 
is anticipated to follow:
 ► Cognitive–behavioural therapy.
 ► Dialectical behaviour therapy.
 ► Family therapy.
 ► Group therapy.
 ► Mentalisation, psychodynamic, cognitive analytic 
therapy.
 ► Multisystemic therapy.
 ► Pharmacological intervention.
 ► Problem solving, psychoeducation, support.
 ► Postcards, tokens, documents.
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Controls
Any inactive (eg, treatment as usual, management as 
usual, placebo or attention control) or any active control.
Outcomes
Primary outcome
Repetition of self- harm. Defined as a cumulative 
binary outcome from randomisation to last available 
follow- up period within 3, 6, 12, 18 and 24 months 
postrandomisation.
The primary time period is 12 months postrandomis-
ation. For the primary outcome, this will include studies 
where the follow- up assessment of self- harm took place 
between >6 and ≤12 months postrandomisation, with self- 
harm measured from randomisation.
Self- harm is defined as any form of intentional non- fatal 
self- poisoning or self- injury (including cutting, taking 
excess medication, attempted hanging, self- strangulation, 
jumping from height, running into traffic), regardless of 
suicidal intent. This includes definitions of non- suicidal 
self- injury commonly used by US researchers and suicidal 
behaviour where lack of intent is assumed by reference to 
the method of self- harm. Self- harm can be self- reported.
Secondary outcomes
 ► Time to repetition of self- harm.
 ► Pattern of self- harm repetition over time.
 ► General psychopathology: score on a self- report 
measure of emotional and behavioural problems.
 ► Depression: score on a self- report measure of 
depression.
 ► Suicidal ideation: score on a self- report measure of 
suicidal ideation.
 ► Quality of life: score on a self- report Quality of Life 
Scale.
 ► Death of adolescent.
Follow- up assessments will be grouped in the short 
term (up to 3 months postrandomisation), and at 6, 12, 
18 and 24 months postrandomisation. Where studies 
include assessments beyond 24 months, data will be 
included where feasible and grouped as ≥24 months 
postrandomisation.
Setting/context
All countries of origin, any method of referral but 
ongoing intervention delivered in outpatient or commu-
nity (school and voluntary sector) settings. This excludes 
intensive inpatient- based interventions as these are 
unlikely to be applicable to UK settings.
Studies
All RCTs, from the first available study, with any 
randomised design (eg, individual or cluster), length of 
follow- up and quality, in which data relating to self- harm 
or suicide attempts have been collected.
We will include studies in which only a subset of partic-
ipants meet our eligibility criteria where we are able to 
obtain IPD for eligible participants, that is, studies with 
only a subset aged 11–18, or not all having self- harmed at 
least once prior to randomisation. Studies with less than 
20 eligible participants will be excluded to ensure the 
logistical effort in obtaining, cleaning and organising the 
data is commensurate with the contribution of the data 
set to the analysis.
Search strategy
A scoping search in 2018 identified five systematic 
reviews7 8 12–14 that identified 22 RCTs meeting RISA- IPD 
eligibility criteria (online supplemental material 1). 
However, assessment of the search strategies and inclu-
sion criteria of these systematic reviews indicated eligible 
studies may have been missed if they were unpublished, 
recently published or contained <85% adolescents as 
participants.
Our search strategy seeks eligible RCTs by two routes to 
ensure exhaustive coverage of relevant systematic reviews, 
and retrieval of eligible studies missed or excluded by 
previous systematic reviews (online supplemental mate-
rial 2):
 ► Literature search for systematic reviews of self- harm 
in adolescents to harvest potentially eligible cited 
RCTs.
 ► Literature searches for recently published RCTs. 
The publication date limit will be the date of the 
searches in the last systematic review that reports an 
exhaustive search. Our scoping searches indicate 
this is likely to be 2015. Also, literature searches for 
unpublished trials (no date restriction) and ongoing 
trials.
We will adhere to European Network for Health Tech-
nology Assessment search guidance.15 The informa-
tion specialist and core team collaborated to develop 
Medline search strategies consisting of text words and 
subject headings for self- harm, suicide behaviours and 
adolescents. One strategy will be limited to systematic 
reviews and a second strategy will be limited to RCTs. 
The Cochrane Collaboration RCT filter is used to iden-
tify studies in Medline. The Medline search strategies are 
reproduced in full in online supplemental material 2. 
The systematic review search will be translated and run 
in Cochrane Database of Systematic Reviews, Embase 
1947+, Epistemonikos, Medline 1946+, PROSPERO and 
PsycINFO 1806+. The RCT search will be translated and 
run in  ClinicalTrials. gov, Cochrane Central Register of 
Controlled Trials, Embase 1947+, Epistemonikos, Europe 
PMC Grant finder, Medline 1946+, National Health and 
Medical Research Council (MRC, Australia), National 
Youth Mental Health Foundation (Headspace), ProQuest 
Dissertations & Theses A&I 1743+, PsycINFO 1806+, Web 
of Science Conference Proceedings Citation Indexes–
Science and Social Science & Humanities 1990+, WHO 
International Clinical Trials Registry Platform. These 
results will be combined in an EndNote library and 
screened/selected using Covidence software. The search 
for RCTs will be repeated 9 months prior to the end of 
the project.
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Review strategy/selection process
Studies will be identified using the search strategy above. 
Two reviewers (DC, AWH) will review titles and abstracts, 
referring to full text and a third nominated reviewer 
(RW) as necessary, to select:
1. Systematic reviews containing RCTs of interventions 
for self- harm in adolescents.
2. Trials (from the RCT literature search and those har-
vested from selected systematic reviews) using agreed 
eligibility criteria. The reference lists of included stud-
ies will be checked for further relevant RCTs.
Data collection
Study-level data collection and risk of bias
Papers, full protocols and statistical analysis plans will 
be obtained following enquiries to RCT chief investiga-
tors and statisticians, and data extracted on study quality 
(at the outcome and study level) by two reviewers (DC, 
AWH); authors will be contacted for further information 
as required.
The quality of identified eligible studies (ie, those 
contributing IPD and/or aggregate data) will be evalu-
ated independently by at least two reviewers (DC, AWH) 
using the Risk of Bias 2 assessment tool.16 Criteria cover 
random sequence generation, allocation concealment, 
blinding of participants, outcome assessment and missing 
data. We will further evaluate additional sources of bias 
common to complex intervention RCTs (eg, allocation 
of therapists to participants, therapist- level missing data). 
Each domain will be judged as contributing to a low, high 
or unclear risk of bias.
Assessment will take place following identification of 
eligible studies based on published papers and proto-
cols irrespective of the availability of IPD. Further assess-
ment will be conducted for included studies after IPD 
are obtained, to allow data quality to be assessed in more 
detail. Studies will be included in the primary analysis 
regardless of study quality and adjusted for in planned 
meta- regression; sensitivity analyses will exclude studies 
judged as having an unclear or high risk of bias.
IPD collection
As recommended by MRC and the Cochrane Collabora-
tion17 we will invite senior authors of each eligible study 
to join a study collaborative group. Multidisciplinary, 
cross- cultural membership of the collaborative group will 
ensure the data used are properly understood and used 
appropriately in the analysis to provide a more global 
and balanced interpretation of the meta- analysis results. 
Regular, informal contact between the study team and 
collaborators is expected as questions arise about indi-
vidual studies. We will invite members of the collabora-
tive group to be involved in and comment on drafts of 
primary publications and to be named as authors of those 
publications.
We will contact study authors of eligible studies to seek 
the following IPD:
 ► Baseline participant demographic and clinical data: 
age, gender, ethnicity, intellectual disability, LGBT 
status, history of abuse, looked after children, self- 
harm method, number and timing of previous self- 
harm attempts, comorbid psychiatric conditions 
(depression, borderline personality disorder and 
unemotional/callous traits, eating disorders, anxiety 
disorders).
 ► Details of therapeutic intervention: attendance, 
session frequency and duration, intensity, overall 
duration, therapist details.
 ► Outcomes: repetition of self- harm, suicide attempt: 
incidence and time to event, and associated data 
(severity, method, outcome, type of event—self- 
reported or clinical/hospital presenting). General 
psychopathology (emotional and behavioural prob-
lems), depression, suicidal ideation and quality of 
life collected using standardised validated measures 
at baseline and all available time points postrando-
misation. Death of adolescent: incidence and time to 
event.
Data collection will be prioritised for the primary 
outcome repetition of self- harm.
Collection and collation of data will be coordinated 
by the team based at the Clinical Trials Research Unit 
(CTRU) at the University of Leeds. Participating study 
authors will be asked to provide pseudonymised (without 
identifying data) data sets in whatever format is conve-
nient to them, along with data dictionaries, original statis-
tical analysis plans and relevant statistical programming 
code, where possible. Data sharing and transfer will be 
subject to formal data sharing agreements signed by the 
University of Leeds and collaborating institutions.
We will make regular contact with study authors 
throughout the project and continue to seek to reach 
agreement with study authors to share data up to within 
2 months of the start of analysis in order to allow suffi-
cient resource for management of the data. IPD from 
studies will be excluded (by necessity) if it is not possible 
to reach agreement with study authors to share data, or 
not possible to obtain good quality translations of non- 
English reports by this time.
Management of IPD
A copy of the raw data obtained from each study will be 
archived and saved in a restricted folder on receipt, prior 
to any modification of the data. Published statistics and 
analyses will be replicated where possible to identify the 
variables used, and to check the data to ensure accuracy 
and quality. Issues and discrepancies found will be raised 
and rectified with the study author. Individual study data 
sets will be reformatted to facilitate the merge across 
studies. Variables will be derived as required and the 
resulting data set locked for analysis.
All information collected during the course of the 
study will be kept strictly confidential. The CTRU will 
comply with all aspects of the 2018 Data Protection Act, 
which incorporates the European Union General Data 
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Protection Regulation. At the end of the study, orig-
inal data sets provided by collaborating trialists will be 
destroyed and the study data set securely archived at the 
CTRU for a minimum of 5 years.
Patient and public involvement
A service user advisory group has been established 
comprising four young people, aged 14–16, who are 
current service users with a personal experience of self- 
harm. Involvement of the group includes:
 ► Educating and familiarising the group and their 
parents/carers with the research methods.
 ► Discussion of the research questions, ensuring these 
reflect the needs and priorities of patients and the 
public.
 ► Ensuring relevant subgroups of participants are 
investigated.
 ► Reviewing and commenting on the progress of the 
research, emerging research results, interpretation 
and relevance to young people and their parents/
carers.
 ► Helping write the plain English summary of research 
outputs.
 ► Helping disseminate research outputs through social 
media, blogs and conferences.
Data synthesis
Statistical considerations
Analyses will be conducted in accordance with current 
recommendations for IPD meta- analyses18–23 and will 
consider appropriate adjustment for baseline covariates 
(prognostic factors), handling of multiple treatment 
groups and control arms, missing data,24–27 repeated 
measures,28 29 timing of outcomes, randomisation, within- 
study treatment- related clustering30 31 and non- adherence.
Analysis populations will be based on the intention- to- 
treat principle, including all randomised participants in 
the groups to which they were randomised, regardless of 
withdrawal or protocol compliance.
Descriptive analysis
Study- level, arm- level, care provider- level and participant- 
level characteristics of included studies will be summarised. 
We will compare these characteristics to studies that were 
eligible but did not supply IPD, to determine if the IPD 
studies are a representative and unbiased sample of all 
eligible studies. Funnel plots of the reported effect size 
of included studies will assess potential publication bias.32 
Outcomes of included studies will be summarised, as will 
adolescent- level and study- level moderators specified in 
subsequent analysis.
Missing data
Missing (outcome/participant/study level) data will 
be summarised, distinguishing between ‘systematically 
missing’ (missing for all participants within a study) and 
‘sporadically missing’ data (incomplete data observed for 
at least some individuals within a study). We will assess 
missing data mechanisms by comparing characteristics of 
studies and participants with and without follow- up data. 
Missing data will be handled in each study separately 
using appropriate methods for dealing with missing data 
in an RCT.24–27
Effect measures
Where outcomes comprise binary data, logistic regression 
will be used to produce OR estimates of the effect of treat-
ment; results will be re- expressed as risk differences and 
relative risks to aid interpretation.
Where sufficient time- to- event data are available for 
outcomes repetition of self- harm and death, Cox propor-
tional hazards regression will be used to produce HR esti-
mates of the effect of treatment; absolute differences will 
be estimated from the model at relevant time periods.
Linear regression will be used to estimate the absolute 
mean difference in treatment effect where outcomes 
comprise continuous data from the same scales; where 
outcomes comprise continuous data from different 
scales, we will estimate the standardised mean difference 
(SMD), standardised according to the total SD.30 31
Analysis of the pooled treatment effect (objective 3.1)
Analysis will be conducted for all primary and secondary 
outcomes separately for each group of studies categorised 
according to therapeutic intervention. Outcomes for each 
time period will be analysed separately; however, where 
possible, we will also conduct multivariate two- stage IPD 
meta- analysis to include all time periods in the same anal-
ysis model, to borrow strength across time periods.28 29
Analysis will be based on a two- stage approach using 
IPD to estimate the intervention effect in each study sepa-
rately, followed by meta- analysis to pool aggregate results. 
Estimates of the intervention effect for the primary 
outcome, repetition of self- harm, will also be conducted 
using a one- stage IPD meta- analysis to explore whether 
estimates are consistent and robust to different estima-
tion methods and modelling decisions.19 21
Stage 1 analysis using logistic, linear and Cox propor-
tional hazards regression (as appropriate to outcome) will 
adjust for a few key participant- level prognostic factors 
defined before any analysis and restricted to strong prog-
nostic factors that are available in all (or most) avail-
able studies. Analysis will also account for within- study 
clustering of participants (ie, cluster randomisation, 
treatment- related clustering) using appropriate methods 
for each study. Where treatment effect is expressed as the 
SMD, primary analysis will not account for within- study 
clustering due to the additional complexity arising from 
the presence of repeated measurements for the estimated 
variation on which to standardise outcomes.28–31
Stage 2 analysis will estimate the pooled treatment 
effect using the random effects approach, assuming a 
normal distribution of treatment effects across studies 
allowing for heterogeneity in treatment effect caused by 
different study characteristics. A fixed effects approach 
will be used where necessary for binary outcomes with 
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rare events (<10%) and multivariate analysis including all 
time periods.28 29
Estimation will use restricted maximum likelihood 
(REML)23 for both one- stage and two- stage analyses 
using a pseudolikelihood approach for one- stage anal-
ysis of the binary primary outcome. CIs will be derived 
using an approach to account for uncertainty in variance 
estimates, such as the Hartung- Knapp- Sidik- Jonkmann22 
approach in the two- stage analysis, and the Kenward- 
Roger or Satterthwaite approach following the one- stage 
analysis.21
After the meta- analysis, we will report estimated 
summary treatment effects, 95% CIs and 95% prediction 
intervals alongside forest plots with study- specific esti-
mates of treatment effect. Heterogeneity will be assessed 
using the τ2 statistic (variability of the true effect sizes 
under the random effects model, estimated using REML) 
and the I2 statistic (proportion of total variability due to 
between- study heterogeneity).
Analysis of adolescent subgroups (objective 3.2)
Provided sufficient data are available, we will investigate 
whether treatment effects for groups of therapeutic inter-
ventions are consistent across adolescent subgroups. 
Analyses will be carried out on the primary outcome, 
repeated for secondary outcomes, either where specified 
a priori or where evidence of subgroup effects is found on 
the primary outcome to check for consistency. Subgroups 
will be included in analysis if represented in a sufficient 
number of studies; studies not collecting the moderator 
of interest will not be included. Adolescent subgroups will 
be agreed by the project management and collaborator 
group, and are likely to consist of:
 ► Age: as a continuous variable.
 ► Sex: male, female.
 ► Ethnicity: White, other.
 ► Identifies as LGBT or not.
 ► Autistic spectrum disorder: present, absent.
 ► History of abuse: yes, no.
 ► Presenting self- harm method: self- injury, self- 
poisoning, combined.
 ► Number and timing of previous self- harm attempts: 
one, two, multiple.
 ► Family dysfunction.
 ► Comorbid psychiatric conditions: depression, border-
line personality disorder, unemotional/callous traits, 
eating disorders, anxiety disorders.
The two- stage Analysis of the pooled treatment effect (objec-
tive 3.1) will be extended to investigate adolescent- level 
subgroup effects separately for groups of studies cate-
gorised according to therapeutic intervention. The first 
stage will include the adolescent subgroup as a fixed 
main effect and moderator- by- treatment interaction. The 
second stage will pool the interaction effects in a random 
effects meta- analysis to account for between- study heter-
ogeneity in the within- study moderator- by- treatment 
interaction.
IPD meta- analysis will increase the power to detect 
genuine subgroup effects. To ensure effects detected are 
not due to chance finding in a single study, subgroup 
effects will be examined for consistency across studies and 
presented in a forest plot.
Analysis of moderating study and intervention effects (objective 
3.3)
The effect of therapeutic interventions may vary across 
studies due to additional sources of between- study 
heterogeneity. This includes clinical diversity due to 
variability in participants or intervention delivery (eg, 
number and duration of sessions) and methodological 
diversity due to variability in study conduct and design 
(eg, age of study, country, data collection and outcome 
measurement, risk of bias). Provided sufficient data and 
studies are available, meta- regression will explore poten-
tial clinical and methodological study- level moderators 
of treatment effect.
IPD random effects meta- regression will extend the 
two- stage meta- analysis used to obtain estimates of the 
pooled treatment effect (objective 3.1) and adolescent 
subgroups (objective 3.2). Potential study- level moderators 
will be included as fixed main effects in the stage 2 meta- 
regression model to investigate if there are any substan-
tial differences in the effect of treatment by moderator. 
Forest plots depicting the individual study and pooled 
treatment effects for different levels of moderators will 
be presented.
Analyses will be carried out on the primary outcome 
separately for groups of studies categorised according 
to therapeutic intervention and will be repeated for 
secondary outcomes where evidence of subgroup effects 
is found on the primary outcome to check for consistency.
Sensitivity analyses
Sensitivity analysis will test the robustness of our conclu-
sions for the analysis of the primary outcome. These will 
include methods for handling missing data,24–27 within- 
study clustering effects for SMDs,30 31 non- adherence and 
study quality.
Unavailable IPD data
Where IPD are not obtained for eligible studies, we will 
use two- stage meta- analysis to incorporate aggregate data 
from studies lacking IPD (using published sources).33 34 
Analysis will explore the impact on estimates of the pooled 
treatment effects (objective 3.1) and moderating study 
effects (objective 3.3). Analysis of adolescent subgroups 
(objective 3.2) will be dependent on availability of suitable 
aggregate data.
Confidence in cumulative evidence
To evaluate the strength of the body of evidence, we will 
report findings alongside our risk of bias assessment for 
individual studies16 and an assessment of potential publi-
cation bias via funnel plot asymmetry.32
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ETHICS AND DISSEMINATION
Formal ethical approval for the project is provided by the 
University of Leeds, Faculty of Medicine and Health Ethics 
Committee (MREC 18-098). The project is sponsored by 
the University of Leeds (RG.PSRY.116370) and funded 
by the National Institute for Health Research Health 
Technology Assessment Programme in the UK following 
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